Search for dissertations about: "tumour markers in breast cancer"

Showing result 1 - 5 of 28 swedish dissertations containing the words tumour markers in breast cancer.

2. 1. Studies of tamoxifen resistance in breast cancer

   Author : Pia Palmebäck Wegman; Sten Wingren; Nils Wilking; Linköpings universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Breast cancer; tamoxifen; polymorphism; metabolic enzymes; oestrogen synthesis; Oncology; Onkologi;

   Abstract : Oestrogen is one of the most important hormonal regulators and is known to play a key role in the development and growth of breast cancer. The majority of tumours have a hormone dependent growth, and this is indicated by the presence of oestrogen receptors (ERs). READ MORE

4. 2. The role of stroma-derived substances in breast cancer progression and their function as tumour markers

   Author : Malin Jansson; Malin Sund; Daniel Öhlund; Ola Billing; Emma Niméus; Umeå universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Breast cancer; perlecan; type IV collagen; type I collagen; extracellular matrix; tumour biomarkers; Surgery; kirurgi;

   Abstract : Background: In 2020, more than 2,260,000 women were diagnosed with breast cancer. Most patients are cured with surgery and adjuvant treatment, but despite that, approximately 700,000 women die of the disease every year. The historical focus on breast cancer progression has been on the malignant epithelial cell. READ MORE

5. 3. TISSUE MICROARRAY PERSPECTIVES ON CYCLIN D1 IN BREAST CANCER: Progression, prognosis and prediction

   Author : Karin Jirström; Tumörmikromiljö; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pathological anatomy; General pathology; tamoxifen resistance; CCND1; Breast cancer; tissue microarrays; Patologi allmän ; patologisk anatomi;

   Abstract : Breast cancer is a truly heterogenous disease, reflected in the existence of a wide spectrum of phenotypic subsets of tumours with varying intrinsic aggressiveness as well as ability to respond to a given treatment. Recent advances in large-scale genomic and proteomic screening techniques have confirmed this heterogeneity also at a molecular level, but there is still a bottleneck to be overcome before the discoveries in the laboratory can be translated into the much more complex clinical situation in order to develop better targeted therapies. READ MORE

6. 4. Theranostic Targeting of GRPR and PSMA in Prostate Cancer

   Author : Ayman Abouzayed; Anna Orlova; Ulrika Rosenström; Anzhelika Vorobyeva; Bogdan Mitran; Cristina Müller; Uppsala universitet; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; prostate cancer; gastrin-releasing peptide receptor GRPR ; prostate-specific membrane antigen PSMA ; nuclear medicine; molecular imaging; radiotracers; theranostics; Farmaceutisk vetenskap; Pharmaceutical Science; Oncology; Onkologi;

   Abstract : This thesis is based on five original articles that investigated the theranostics of prostate cancer by gastrin-releasing peptide receptor (GRPR) and prostate-specific membrane antigen (PSMA) targeting. GRPR and PSMA are two extensively evaluated prostate cancer cell markers due to their overexpression in the majority of prostate cancer samples. READ MORE

7. 5. Tamoxifen response in primary breast cancer with special reference to tumour-specific VEGF-A and VEGFR2

   Author : Lisa Rydén; Lund Kirurgi; []
   Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Cytology; oncology; cancerology; Cytologi; onkologi; cancer; prognosis; randomised controlled trial; adjuvant tamoxifen treatment; vascular endothelial growth factor receptor 2; breast cancer; vascular endothelial growth factor A;

   Abstract : Background: Treatment of primary breast cancer is individualised and adjuvant systemic treatment is delivered to most patients after surgery. Oestrogen receptor (ER) status and progesterone receptor status (PR) can define patients who would benefit from adjuvant endocrine therapy with tamoxifen (TAM) alone or as chemo-endocrine therapy. READ MORE